CD19/BCMA in vivo CAR-T
CD19/BCMA IIT for ADs
Phase 1 small_molecule active
Quick answer
CD19/BCMA in vivo CAR-T for Autoimmune Diseases is a Phase 1 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Autoimmune Diseases
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active